Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United StatesRobert I. Haddad, Kevin J. Harrington, Ezra E.W. Cohen et al.|Journal of Medical Economics|2020Cited by 28
Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinAlpesh Amin, Jeffrey Trocio, Onur Başer et al.|Circulation|2015Cited by 4
Comparison of Short-Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or WarfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|CHEST Journal|2015Cited by 3
Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinAmin N Alpesh, Jeffrey Trocio, Allison Keshishian et al.|Blood|2015Cited by 3
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient settingHenry J. Henk, Lien Vo, Feng Cao et al.|Current Medical Research and Opinion|2017Cited by 2